Literature DB >> 26148264

Response to Licinio et al.

Ken Sato1, Kenichi Hosonuma2, Motoyasu Kusano3, Masanobu Yamada1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26148264     DOI： 10.1038/ajg.2015.166

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  5 in total

1.  Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis.

Authors:  H Rautiainen; M Färkkilä; M Neuvonen; T Sane; A-L Karvonen; H Nurmi; P Kärkkäinen; P J Neuvonen; J T Backman
Journal:  Aliment Pharmacol Ther       Date:  2006-12       Impact factor: 8.171

2.  Combination Therapy of Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis: The End of the Steroid Era in Autoimmune Liver Diseases?

Authors:  Raffaele Licinio; Antonio Facciorusso; Nicola Maurizio Castellaneta; Alfredo Di Leo
Journal:  Am J Gastroenterol       Date:  2015-07       Impact factor: 10.864

3.  Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.

Authors:  M Leuschner; K P Maier; J Schlichting; S Strahl; G Herrmann; H H Dahm; H Ackermann; J Happ; U Leuschner
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

4.  A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.

Authors:  Kenichi Hosonuma; Ken Sato; Yuichi Yamazaki; Masatoshi Yanagisawa; Hiroaki Hashizume; Norio Horiguchi; Satoru Kakizaki; Motoyasu Kusano; Masanobu Yamada
Journal:  Am J Gastroenterol       Date:  2015-03-03       Impact factor: 10.864

5.  Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial.

Authors:  Henna Rautiainen; Päivi Kärkkäinen; A-L Karvonen; Heimo Nurmi; Pekka Pikkarainen; Hannu Nuutinen; Martti Färkkilä
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.